Lung tumor markers of cytokeratin origin: an overview

被引:44
作者
Buccheri, G [1 ]
Ferrigno, D [1 ]
机构
[1] Osped S Croce & Carle, Div Pneumol, I-12100 Cuneo, Italy
关键词
tumor markers; bronchogenic carcinoma; cytokeratins; cytoskeleton; tissue polypeptide antigen; tissue polypeptide specific-antigen; cytokeratin; 19; fragments;
D O I
10.1016/S0169-5002(01)00347-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung tumor markers fall into several categories including oncofetal proteins, structural proteins and their fragments, enzymes, membrane antigens, peptide and non-peptide hormones. Cytokeratins (Ch) are well known structural proteins whose degradation gives rise to soluble fragments, measurable in the blood of patients and capable of cancer marking. Among them, Tissue Polypeptide Antigen (TPA), Tissue Polypeptide-Specific Antigen (TPS) and Cytokeratin-19-Fragments (Cyfra 21-1) are the most studied CK fragments' complexes. This article will review biological characteristics and clinical properties of these substances, emphasizing as their concentration in the peripheral blood might reflect the mass of tumor, the rate of cancer cell lysis, and other potentially unfavorable tumor characteristics. Assaying the concentration of CK fragments in the blood is an easy and effective way to assess lung cancer and monitor its clinical evolution. (C) 2001. Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S65 / S69
页数:5
相关论文
共 52 条
[1]  
*AM THOR SOC, 1998, AM J RESP CRIT CARE, V156, P320
[2]   Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer [J].
Bates, J ;
Rutherford, R ;
Divilly, M ;
Finn, J ;
Grimes, H ;
O'Muircheartaigh, I ;
Gilmartin, JJ .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (11) :2535-2538
[3]   ANTIGENICITY OF POOLED HUMAN MALIGNANT AND NORMAL TISSUES BY CYTO-IMMUNOLOGICAL TECHNIQUE - PRESENCE OF AN INSOLUBLE, HEAT-LABILE TUMOR ANTIGEN [J].
BJORKLUND, B ;
BJORKLUND, V .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1957, 10 (03) :153-184
[4]  
BJORKLUND B, 1973, IMMUNOLOGICAL TECHNI, P133
[5]  
Bodenmuller H, 1992, TUMOR ASS ANTIGENS O, P137
[6]  
BROERS JLV, 1988, CANCER RES, V48, P3221
[7]   MONITORING LUNG-CANCER WITH TISSUE POLYPEPTIDE ANTIGEN - AN ANCILLARY, PROFITABLE SERUM TEST TO EVALUATE TREATMENT RESPONSE AND POSTTREATMENT DISEASE STATUS [J].
BUCCHERI, G ;
FERRIGNO, D .
LUNG CANCER, 1995, 13 (02) :155-168
[8]   PROGNOSTIC FACTORS IN LUNG-CANCER - TABLES AND COMMENTS [J].
BUCCHERI, G ;
FERRIGNO, D .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (07) :1350-1364
[9]   USEFULNESS OF TISSUE POLYPEPTIDE ANTIGEN IN STAGING, MONITORING, AND PROGNOSIS OF LUNG-CANCER [J].
BUCCHERI, G ;
FERRIGNO, D .
CHEST, 1988, 93 (03) :565-570
[10]  
Buccheri G, 1999, LUNG BIOL HEALTH DIS, V124, P435